# Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)

> **NCT01564459** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 170 (actual)

## Conditions studied

- Diabetic Neuropathy, Painful

## Interventions

- **DRUG:** MK-6096
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01564459
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-26
- **Primary completion:** 2013-04-18
- **Final completion:** 2013-04-18
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01564459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01564459, "Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01564459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*